Trial Profile
An Exploratory Trial of AZD3480 (TC-1734) [ispronicline] for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ispronicline (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 04 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Nov 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.